Abstract
This chapter will discuss the various approaches to cancer vaccine development. It will begin with information about cancer and its available treatments. Furthermore, prophylactic and therapeutic cancer vaccines will be discussed in detail. We will also discuss (1) potential antigens, such as tumor-associated antigens, neoantigens, and oncogenic viral antigens that can be targeted through vaccination; (2) various vaccine development techniques, such as a peptide, nucleic acid, whole cell, dendritic, particle-based, and in situ vaccines, that are utilized in cancer vaccine development; (3) approved vaccines and vaccines in clinical trials; (4) the role of adjuvants in stimulating the immune system for greater antitumor efficacy; (4) resistance mechanisms that decrease or abrogate the efficacy of vaccines; and (5) the use of vaccines, in combination with other treatments to increase the efficacy and decrease resistance.
| Original language | English |
|---|---|
| Title of host publication | Advanced Vaccination Technologies for Infectious and Chronic Diseases |
| Subtitle of host publication | A Guide to Vaccinology |
| Publisher | Elsevier |
| Pages | 357-390 |
| Number of pages | 34 |
| ISBN (Electronic) | 9780443185649 |
| ISBN (Print) | 9780443185656 |
| DOIs | |
| State | Published - 1 Jan 2024 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Anti-CTLA-4
- Anti-PD1
- Cancer immunotherapy
- Neoantigen
- Prophylactic cancer vaccine
- Therapeutic cancer vaccine
- Tumor-associated antigen
- Vaccine resistance
Fingerprint
Dive into the research topics of 'New approaches to vaccines for cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver